
|Videos|October 11, 2016
Atopic Dermatitis: Reimbursement Challenges
Advertisement
Episodes in this series

Panelists Peter L. Salgo, MD; Ed Pezalla, MD, MPH; Jeffrey D. Dunn, PharmD, MBA; Cheryl Allen, BS Pharm, MBA; and Jonathan Silverberg, MD, PhD, MPH, outline translating clinical trial results and some of the reimbursement challenges when treating patients with atopic dermatitis.
Advertisement
Related to this article

Brooke Hudspeth, Nicole Paolini Albanese, and Joshua Neumiller explain how pharmacists spot patterns, fix testing problems, and brief the care team.

Extended INDIGO and FIREFLY-1 results presented at SNO 2026 put seizure burden during vorasidenib therapy and time off tovorafenib in pediatric low-grade glioma into focus.

With a mifepristone safety review due by March and Senate control shifting in January, the FDA faces an extended stretch without a permanent leader.

Pharmacists can help patients start buprenorphine for opioid use disorder by confirming when to take the first dose, whether another opioid continues during initiation, and who will manage symptoms and follow-up.

In older veterans, mRNA-1283 was associated with lower risks of medically attended COVID-19 and hospitalization than BNT162b2.

Pharmacists can use medication therapy management to screen for diabetes, educate patients about medication adherence and lifestyle modifications, and support early action.

In a phase 3 trial of children aged 6 to younger than 12 years, once-weekly semaglutide reduced BMI 16.2 percentage points more than placebo at 68 weeks.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Two-Drug HIV Regimens, Archived M184V Resistance, and Long-Acting Preference
2
Long-Acting HIV Injectables in Viremia and New Tenofovir-Free Oral Options
3
SNO 2026 Roundup: What Longer Follow-Up Means for Targeted Glioma Care
4
Overton FDA Nomination Withdrawn: What It Means for Pharmacists
5




















